Judy Boughey, SABCS 2022: Breast conservation therapy in patients with multiple ipsilateral breast cancer – The ACOSOG (Alliance) Z11102 trial
The ACOSOG (Alliance) Z11102 (NCT01556243) phase II single arm prospective trial evaluated how well breast-conserving surgery and radiation therapy worked in treating patients with multiple ipsilateral breast cancer. In this touchONCOLOGY interview, we speak with Prof. Judy Boughey (Mayo Clinic, Rochester, MN, USA) who gives an overview on multiple ipsilateral breast cancer and also discusses the ACOSOG (Alliance) Z11102 trial.
The abstract entitled ‘Impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer – Results from ACOSOG Z11102 (Alliance)’ was presented at San Antonio Breast Cancer Symposium (SABCS), 06–10, December, 2022.
- Could you tell us a little about multiple ipsilateral breast cancer (MIBC) and its improved detection? (0:14)
- What is known about the optimal surgical management of MIBC? (0:36)
- What were the aims, design and eligibility criteria of the ACOSOG Z11102 study? (1:23)
- What were the primary and secondary outcome measures, and how well were they achieved? (2:30)
- What factors impacted local recurrence? (3:48)
Disclosures: Judy Boughey discloses grant/research support from Eli Lilly
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen
Filmed as a highlight of SABCS 2022
Access more content on Breast Cancer
Share this Video
Related Videos In Breast Cancer
Sara Hurvitz, SABCS 2022: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2+ metastatic breast cancer: DESTINY-Breast03
Trastuzumab deruxtecan (T-DXd) is approved in the United States and European Union for use in patients with HER2+ unresectable/metastatic breast cancer. Approval was based on the randomized, multicenter, open-label, phase III DESTINY-Breast03 (NCT03529110) trial. In this interview we discuss with Dr Sara Hurvitz (David Geffen School of Medicine, UCLA Los Angeles, CA, USA) updated data […]
Erika Hamilton, SABCS 2022: Trastuzumab deruxtecan and pertuzumab in HER2+ metastatic breast cancer
Preclinical findings have suggested that when used in combination with anticancer treatments, trastuzumab deruxtecan (T-Dxd) could improve treatment efficacy in HER2+ metastatic breast cancer (mBC). In this interview we discuss with Dr Erika Hamilton (Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN) preliminary data from the dose expansion phase of the DESTINY-Breast07 (DB-07) (NCT04538742) trial. […]
Sudeep Gupta, SABCS 2022: Addition of platinum to neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial
The impact of adding platinum on long-term outcomes in triple-negative breast cancer (TNBC) has not been definitively established. The controlled, single-centre, phase III study conducted by Tata Memorial Hospital in Mumbai, India evaluated the efficacy and toxicity of adding platinum to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer. In this touchONCOLOGY interview, we speak […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!